Cytotoxicities of three rebeccamycin derivatives in the National Cancer Institute screening of 60 human tumor cell lines

Anti-Cancer Drugs

Volumn 16, Issue 2, 2005, Pages 145-150

  Moreau, Pascale ^a   Holbeck, Susan ^b   Prudhomme, Michelle ^a   Sausville, Edward A ^b  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

COMPARE analysis; Cytotoxicity; DNA binding; Indolocarbazoles; Inhibition; Topoisomerase I

Indexed keywords

BMS 181176; CARBAZOLE DERIVATIVE; DNA TOPOISOMERASE; INDOLE DERIVATIVE; NSC 726576; NSC 726577; NSC 726578; POISON; REBECCAMYCIN;

ARTICLE; BREAST CANCER; CELL STRAIN HT29; CELL STRAIN K 562; CENTRAL NERVOUS SYSTEM TUMOR; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG DNA BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; KIDNEY CANCER; LEUKEMIA L 1210; MELANOMA CELL; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARBAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 13844267548     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200502000-00005     Document Type: Article

References (18)

1. Pindur U, Kim Y-S, Mehrabani F. Advances in indolo[2,3-a]carbazole chemistry: design and synthesis of protein kinase C and topoisomerase I inhibitors. Curr Med Chem 1999; 6:29-69.
2. Prudhomme M. Recent developments of rebeccamycin analogues as topoisomerase I inhibitors and antitumor agents. Curr Med Chem 2000; 7:1189-1212.
3. Prudhomme M, Anizon F, Moreau P. Recent developments in the synthesis of indolocarbazoles, topoisomerase I inhibitors. Recent Res Dev Synth Organic Chem 1999; 2:79-106.
4. Rodrigues-Pereira E, Belin L, Sancelme M, Prudhomme M, Ollier M, Rapp M, et al. Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. J Med Chem 1996; 39:4471-4477.
5. Bush JA, Long JJ, Catino WT, Bradner K, Tomita K. Production and biological activity of rebeccamycin, a novel antitumor agent. J Antibiotics 1987; 40:668-678.
6. Bailly C, Riou J-F, Colson P, Houssier C, Rodrigues-Pereira E, Prudhomme M. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. Biochemistry 1997; 36:3917-3929.
7. Anizon F, Belin L, Moreau P, Sancelme M, Voldoire A, Prudhomme M, et al. Syntheses and biological activities (Topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. J Med Chem 1997; 40:3456-3465.
8. Moreau P, Anizon F, Sancelme M, Prudhomme M, Bailly C, Carrasco C, et al. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle. J Med Chem 1998; 41:1631-1640.
9. Anizon F, Moreau P, Sancelme M, Voldoire A, Prudhomme M, Ollier M, et al. Syntheses, biochemical and biological evaluation of staurosporine analogues from microbial metabolite rebeccamycin. Bioorg Med Chem 1998; 6:1597-1604.
10. Anizon F, Moreau P, Sancelme M, Laine W, Bailly C, Prudhomme M. Rebeccamycin analogues bearing amine substituents or other groups on the sugar moiety. Bioorg Med Chem 2003; 11:3709-3722.
11. Moreau P, Gaillard N, Marminon C, Anizon F, Dias N, Baldeyrou B, et al. Semi-synthesis, topoisomerase I and kinases inhibitory properties, and antiproliferative activities of new rebeccamycin derivatives. Bioorg Med Chem 2003; 11:4871-4879.
12. Moreau P, Anizon F, Sancelme M, Prudhomme M, Bailly C, Severe D, et al. Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent. J Med Chem. 1999; 42:584-592.
13. Moreau P, Anizon F, Sancelme M, Prudhomme M, Sevėre D, Riou J-F, et al. Synthesis, mode of action, and biological activities of rebeccamycin bromoderivatives. J Med Chem 1999; 42:1816-1822.
14. Gray N, Dėtivaud L, Doerig C, Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem. 1999; 6:859-875.
15. Moreau P, Sancelme M, Bailly C, Léonce S, Pierré A, Hickman J, et al. Synthesis and biological activities of indolocarbazoles bearing amino acid residues. Eur J Med Chem 2001; 36:887-897.
16. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Nat Cancer Inst 1991; 83:757-766.
17. Skehan P, Storeng R, Scudiero D, Monk A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-1112.
18. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989; 81:1088-1092.